Elementa Labs will connect health care startup companies with Mount Sinai’s vast network of research and clinical experts to advance groundbreaking health care innovations.
If authorized for quantitative use, the assay could be used to provide a numeric result for the concentration of neutralizing anti-COVID-19 antibodies in plasma.
– Kantaro Biosciences partners with Bio-Techne for manufacturing and global kit distribution
– Scaled kit production to enable clinical laboratories to conduct 10M tests per month is planned to begin in July
Collaboration combines Harbour BioMed’s proprietary H2L2 Harbour Mice® platform for fully human monoclonal antibody generation with Mount Sinai’s translational medical research expertise.